October 21, 2017 1:01 PM ET

Life Sciences Tools and Services

Company Overview of The EMMES Corporation

Company Overview

The EMMES Corporation operates as a contract research organization. Its products include EMMES AdvantageEDC, a platform that provides study design tools and data collection in electronic case report forms and data quality management; EMMES RTS, a platform to assist in coordination, collection, organization, and retrieval of regulatory documentation for investigational sites; and EMMES GlobalTrace, a materials/specimen management platform that tracks in real-time from collection at a clinical site to arrival and storage at a central laboratory or repository. The company’s services include statistical leadership and project management, study design and protocol development, Web-based data coll...

401 North Washington Street

Suite 700

Rockville, MD 20850

United States

Founded in 1977





Key Executives for The EMMES Corporation

Chief Executive Officer and President
Chief Financial Officer and Vice President
Chief Operating Officer
Chief Medical Officer
Vice President
Compensation as of Fiscal Year 2017.

The EMMES Corporation Key Developments

Emmes Corp Wins $69.72 Million Federal Contract

Emmes Corp. won a $69,717,369.27 federal contract from the U.S. Department of Health and Human Services National Institutes of Health for support services for Best Pharmaceuticals for Children Act Data Coordinating Center.

The Emmes Corporation Opens New Office in Frederick, MD

The Emmes Corporation announced that it has expanded its operations in greater Washington to include a new office in Frederick, Maryland. The company's decision to open an office in Frederick incorporated feedback from some employees on the length of their commute to the Rockville headquarters. Instead of expanding office space in Rockville, the company decided to seek additional space in Frederick and offered its Rockville staff the opportunity to choose where to wor k.

The Emmes Corporation Expands Zika Vaccine Research Contract

The Emmes Corporation announced a contract spanning just over four years for a Phase 2 study of a Zika vaccine. The contract, valued at up to $27.6 million, expands the initial Phase 1 testing that began last year. This is the first-ever Phase 2 study for a Zika vaccine. The clinical study is being conducted for the National Institute of Allergy and Infectious Disease'sVaccine Research Center at the National Institutes of Health (NIH). The study, titled a Phase 2/2B, Randomized Trial to Evaluate the Safety, Immunogenicity and Efficacy of a Zika Virus DNA Vaccine in Healthy Adults and Adolescents, is being conducted in two parts. Under the contract, the company will lead the data management, statistical, regulatory, and clinical monitoring efforts. The company currently supports the predecessor study, a Phase 1 trial that is testing the same Zika vaccine in 45 subjects. In addition to the Zika studies for the Vaccine Research Center, Emmes supports four other Zika clinical trials.

Similar Private Companies By Industry

Company Name Region
10X Genomics, Inc. United States
4G Clinical, Inc. United States
AAPharmaSyn LLC United States
Abiant, Inc. United States
aBioBot, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
NYC2012, Inc. United States
Tax Management Inc United States
Bertelsmann AG Europe

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact The EMMES Corporation, please visit www.emmes.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.